Hcw Biologics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 353,680 shares, representing 4.99% of HCW Biologics Inc.'s common stock.